InvestSMART

Hexima Limited (ASX: HXL) - Share Price

- Current share price for HXL : $0.013

Hexima Limited (HXL), an ASX-listed company, is a Company that is engaged in exploration of third-party transactions that will realise the value of the Company' assets, including its intellectual property.

HXL General Information +

ASX Code HXL
Website http://www.hexima.com.au
Industry/Sector Biotechnology
Market Cap ($M) 0
HXL Share Price $0.013
Day High $0.000
Day Low $0.000
Last Close $0.013
HXL Share Price Movement - ( No change )
Prices as at 16:40, 26 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Hexima Limited (HXL) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Hexima Limited (HXL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Hexima Limited (HXL) price-sensitive announcements

HXL - Acquisition Update
Hexima Limited has provided an update regarding the acquisition of RealThing Entertainment
Hexima Limited (HXL)
23 Oct 2024 | 5:28 PM
HXL - Extension of Conditions Precedent Satisfaction Date
Hexima Limited (ASX: HXL) announced an extension to the satisfaction date for precondition
Hexima Limited (HXL)
27 Sep 2024 | 8:23 AM
HXL - Appendix 4E
Hexima Limited released its Appendix 4E Preliminary Final Report for the financial year en
Hexima Limited (HXL)
29 Aug 2024 | 3:16 PM
HXL - Business Activity Statement & Appendix 4C - Jun-2024 Qtr
Hexima Limited (ASX:HXL) has released its Appendix 4C quarterly activities report for the
Hexima Limited (HXL)
31 Jul 2024 | 2:03 PM

Hexima Limited (HXL) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Hexima Limited (HXL)
ORDINARY FULLY PAID
 Health Care $1 Business Activity Statement & Appendix 4C - Mar-2026 Qtr 30 Apr 2026 6:10PM $0.013 $0.013 fallen by 0%
Hexima Limited (HXL)
ORDINARY FULLY PAID
 Health Care $1 Long Term Suspended Entities 17 Apr 2026 2:52PM $0.013 $0.013 fallen by 0%
Hexima Limited (HXL)
ORDINARY FULLY PAID
 Health Care $1 Update - Notification of cash return of capital 16 Apr 2026 11:31AM $0.013 $0.013 fallen by 0%
Hexima Limited (HXL)
ORDINARY FULLY PAID
 Health Care $1 Update - Consolidation/Split - HXL 16 Apr 2026 11:29AM $0.013 $0.013 fallen by 0%
Hexima Limited (HXL)
ORDINARY FULLY PAID
 Health Care $1 Results of Meeting 16 Apr 2026 11:16AM $0.013 $0.013 fallen by 0%
Hexima Limited (HXL)
ORDINARY FULLY PAID
 Health Care $1 Consolidation/Split - HXL 13 Mar 2026 8:55AM $0.013 $0.013 fallen by 0%

HXL Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$0.50 -$0.30 -46.40% 0.00 0.00 0.00% 0.0%
2024A -$0.93 -$0.60 -51.30% 0.00 0.00 0.00% 0.0%
2023A -$1.92 -$1.20 -82.50% 0.00 0.00 0.00% 0.0%

HXL Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
CSL Limited (CSL) $55,070M 0.1108 -0.1307 0.0166 12.3304 14.1849 13.9537 3.88% 3.13% 3.26%
Clinuvel Pharmaceuticals Limited (CUV) $514M 0.0287 0.0233 0.0942 14.2061 13.8832 12.6881 0.49% 0.71% 1.15%
Hexima Limited (HXL) $1M -0.4643 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast Limited (MSB) $2,887M 0.0301 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,338M -1.3893 0.0000 -0.1306 0.0000 293.4701 337.5536 0.00% 0.00% 0.00%

HXL Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 1.43 0.00
Market 0.29 13.30 1.15 0.61
Sector 0.43 26.10 2.44 2.36

HXL Directors

Name Position Start Date
Mr Geoffrey Paul Kempler Executive Chairman, Managing Director 5 Sep 2023
Mr Phillip Hains Non-Executive Director 18 Sep 2023
Mr Justin Zhen Nan Yap Non-Executive Director 17 Jul 2018

Hexima Limited (HXL) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
25 Mar 2022 VAN DER WEERDEN, Nicole Transfer Direct Shares 124,160 $0.390 $48,422.400
25 Mar 2022 VAN DER WEERDEN, Nicole Transfer Indirect Shares 124,160 $0.390 $48,422.400
24 Feb 2022 VAN DER WEERDEN, Nicole Buy Direct Shares 250,000 $0.160 $40,000.000

See all changes in directors' interest & trades for Hexima Limited (HXL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

HXL Management

Name Position
Leanne Ralph Company Secretary

HXL Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Hexima Limited (HXL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
28,114,619 (16.83%) Balmain Resources Pty Ltd
17,684,540 (10.59%) Dato Lim Sen Yap
15,126,863 (9.06%) Woobinda Nominees Pty Limited

HXL Calendar of Events

Date Event
26 February 2027 Report (Interim)
28 August 2026 Report (Annual)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.